Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

2022; Massachusetts Medical Society; Volume: 387; Issue: 3 Linguagem: Inglês

10.1056/nejmoa2202809

ISSN

1533-4406

Autores

Javier Cortés, Hope S. Rugo, David W. Cescon, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Jose Manuel Perez‐García, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Xuan Zhou, Vassiliki Karantza, Wilbur Pan, Peter Schmid,

Tópico(s)

HER2/EGFR in Cancer Research

Resumo

In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of 10 or more. The results of the final analysis of overall survival have not been reported.

Referência(s)